Document Classification

Section Type: RESULTS

Text: Irrespective of CrCl, therapy with tirofiban reduced the odds of the composite end point of death, myocardial infarction, or refractory ischemia at 48 hours (odds ratio [OR], 0. 68 ; 95 % confidence interval [CI], 0. 46 to 1. 0 ; P = 0. 05), 7 days (OR, 0. 68 ; 95 % CI, 0. 52 to 0. 88 ; P = 0. 003), 30 days (OR, 0. 78 ; 95 % CI, 0. 63 to 0. 98 ; P = 0. 03), and 6 months (OR, 0. 81 ; 95 % CI, 0. 68 to 0. 98 ; P = 0. 03).